menu search

GLTO / Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint. Read More
Posted: Aug 16 2023, 09:28
Author Name: Zacks Investment Research
Views: 112318

GLTO News  

Galecto to Present at Investor Conferences in September

By GlobeNewsWire
August 31, 2023

Galecto to Present at Investor Conferences in September

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology fo more_horizontal

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

By Zacks Investment Research
August 16, 2023

Galecto (GLTO) Down 71% as Lung Disease Candidate Fails

Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint. more_horizontal

Galecto shares drop 65% as biotech halts development of lung-disease treatment

By Market Watch
August 15, 2023

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idi more_horizontal

Galecto to discontinue development of lung disease treatment

By Reuters
August 15, 2023

Galecto to discontinue development of lung disease treatment

Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid more_horizontal

ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc

By GuruFocus
July 27, 2023

ORBIMED ADVISORS LLC Reduces Stake in Galecto Inc

On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnolo more_horizontal

Orbimed Advisors Now Owns 10.5% of Galecto

By 24/7 Wall Street
April 10, 2023

Orbimed Advisors Now Owns 10.5% of Galecto

Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO). more_horizontal

All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

By Zacks Investment Research
November 11, 2022

All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong more_horizontal


Search within

Pages Search Results: